References of ImmunoglobulinG4 (anti-(human CD33 (antigen)) (human-mouse monoclonal hP67.6 g4-chain)),disulfide with human-mouse monoclonal hP67.6 k-chain, dimer, methylN-[(1R,4Z,8S,13E)-8-[[2-O-[4-(acetylethylamino)-2,4-dideoxy-3-O-methyl-a-L-threo-pentopyranosyl]-4,6-dideoxy-4-[[[2,6-dideoxy-4-S-[4-[(6-deoxy-3-O-methyl-a-L-mannopyranosyl)oxy]-3-iodo-5,6-dimethoxy-2-methylbenzoyl]-4-thio-b-D-ribo-hexopyranosyl]oxy]amino]-b-D-glucopyranosyl]oxy]-13-[2-[[3-[2-[1-[4-(4-amino-4-oxobutoxy)phenyl]ethylidene]hydrazinyl]-1,1-di
Title: Gemtuzumab Ozogamicin
CAS Registry Number: 220578-59-6
Manufacturers' Codes: CDP-771; CMA-676
Trademarks: Mylotarg (Wyeth)
Literature References: Immunoconjugate of
N-acetyl-g-calicheamicin with the humanized mouse monoclonal IgG4 k antibody, hP67.6, directed against the human CD33 antigen located on the surface of normal and leukemic myeloid cells, but not on normal hematopoietic stem cells. Designed to deliver antibody-targeted chemotherapy for treatment of acute myelocytic leukemia (AML). Prepn of conjugate: P. R. Hamann
et al., EP 689845;
eidem, US 5773001 (1996, 1998 both to Am. Cyanamid).
In vitro antineoplastic activity: K. Naito
et al., Leukemia 14, 1436 (2000). Clinical evaluation in AML: E. L. Sievers
et al., Blood 93, 3678 (1999). Reviews of development and therapeutic potential: I. D. Bernstein,
Leukemia 14, 474-475 (2000); I. Niculescu-Duvaz,
Curr. Opin. Mol. Ther. 2, 691-696 (2000); of clinical experience: F. J. Giles,
Expert Rev. Anticancer Ther. 2, 630-640 (2002).
Properties: Sensitive to light; protect from direct and indirect sunlight and unshielded fluorescent light.
Therap-Cat: Antineoplastic
Keywords: Antineoplastic; Monoclonal Antibodies.